Abstract: Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
Type:
Application
Filed:
October 2, 2014
Publication date:
March 26, 2015
Inventors:
JAMES J. ENGLISH, AZALEA S. ONG, NASSER YALPANI
Abstract: The invention relates to recombinant expression of variant forms of M. thermophila CBH1a and homologs thereof, having improved thermoactivity, specific activity, and other desirable properties. Also provided are methods for producing ethanol and other valuable organic compounds by combining cellobiohydrolase variants with cellulosic materials.
Type:
Application
Filed:
March 12, 2013
Publication date:
March 26, 2015
Inventors:
Behnaz Behrouzian, Xinkai Xie, Kui Chan, Xiyun Zhang, Vesna Mitchell, Douglas A. Hattendorf
Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.
Type:
Application
Filed:
September 25, 2014
Publication date:
March 26, 2015
Inventors:
Lawrence M. KAUVAR, Stefan RYSER, Angeles ESTELLES, Robert STEPHENSON, Reyna J. SIMON, Omar NOURZAIE
Abstract: A method of producing a low molecular weight organic compound (e.g. a plant or bacteria secondary metabolite) in increased yields involving use of a microorganism cell, which comprises a gene involved in the biosynthesis pathway leading to a low molecular weight organic aglycon compound and a glycosyltransferase gene capable of glycosylating the produced aglycon.
Type:
Grant
Filed:
August 8, 2011
Date of Patent:
March 24, 2015
Assignee:
Evolva SA
Inventors:
Joergen Hansen, Thomas Hvid Andersen, Finn Thyge Okkels
Abstract: The present invention relates to the use of nucleic acid molecules coding for a bacterial xylose isomerase (XI), preferably coming from Clostridium phytofermentans, for reaction/metabolization, particularly fermentation, of recombinant microorganisms of biomaterial containing xylose, and particularly for the production of bioalcohols, particularly bioethanol, by means of xylose fermenting yeasts. The present invention further relates to cells, particularly eukaryotic cells, which are transformed utilizing a nucleic acid expression construct which codes for a xylose isomerase, wherein the expression of the nucleic acid expression construct imparts to the cells the capability to directly isomerize xylose into xylulose. Said cells are preferably utilized for reaction/metabolization, particularly fermentation, of biomaterial containing xylose, and particularly for the production of bioalcohols, particularly bioethanol.
Type:
Grant
Filed:
July 1, 2009
Date of Patent:
March 24, 2015
Assignee:
Lesaffre et Compagnie
Inventors:
Dawid Brat, Eckhard Boles, Marco Keller, Beate Wiedemann
Abstract: The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods for identifying inhibitors of the interaction of endosialin with endosialin ligands. Also provided are methods for inhibiting angiogenesis and neovascularization in vivo and in vitro.
Type:
Application
Filed:
October 8, 2014
Publication date:
March 19, 2015
Inventors:
Yuhong Zhou, Brian Tomkowicz, Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass
Abstract: The present invention relates to a novel valencene synthase, to a nucleic acid encoding such valencene synthase, to a host cell comprising said encoding nucleic acid sequence and to a method for preparing valencene, comprising converting farnesyl diphosphate to valencene in the presence of a valencene synthase according to the invention.
Abstract: The invention provides bispecific fusion proteins that inhibit activation of complement pathway and vascular endothelial growth factor (VEGF) pathway and methods for using these fusion proteins.
Abstract: The present invention relates to GH61 polypeptide variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
Type:
Application
Filed:
April 26, 2013
Publication date:
March 19, 2015
Inventors:
Janine Lin, Doreen Bohan, Michelle Maranta, Leslie Beresford, Michael Lamsa, Matt Sweeney, Mark Wogulis, Elizabeth Znameroski, Frank Winther Rasmussen
Abstract: Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotropin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.
Abstract: The invention provides non-naturally occurring microbial organisms having a (2-hydroxy-3-methyl-4-oxobutoxy) phosphonate (2H3M40P) pathway, p-toluate pathway, and/or terephthalate pathway. The invention additionally provides methods of using such organisms to produce 2H3M40P, p-toluate or terephthalate. Also provided herein are processes for isolating bio-based aromatic carboxylic acid, in particular, p-toluic acid or terephthalic acid, from a culture medium, wherein the processes involve contacting the culture medium with sufficient carbon dioxide (C02) to lower the pH of the culture medium to produce a precipitate comprised of the aromatic carboxylic acid.
Type:
Application
Filed:
January 18, 2013
Publication date:
March 19, 2015
Applicant:
Genomatica, Inc.
Inventors:
Robin E. Osterhout, Anthony P. Burgard, Mark J. Burk
Abstract: The disclosure relates to a recombinant microorganism engineered to express an enzyme which catalyzes the conversion of a primary amine and an acyl thioester to a fatty amide. The disclosure further encompasses a method of producing a fatty amide by culturing the recombinant microorganism in the presence of a carbon source.
Abstract: The present invention relates to yeast cells producing high levels of acetoacetyl-CoA. It also relates to a method for making such yeast cells and to the use of such yeast cells in a method for producing acetyl-CoA derived products.
Abstract: Disclosed are variants of Humicola grisea CeI7A (CBH1.1), H. jecorina CBH1 variant or S. thermophilium CBH1, nucleic acids encoding the same and methods for producing the same. The variant cellulases have the amino acid sequence of a glycosyl hydrolase of family 7A wherein one or more amino acid residues are substituted.
Type:
Application
Filed:
August 20, 2014
Publication date:
March 19, 2015
Applicant:
Danisco US Inc.
Inventors:
Frits GOEDEGEBUUR, Peter Gualfetti, Colin Mitchinson, Edmund Larenas
Abstract: Some aspects of this invention relate to methods useful for the conversion of a carbon source to a biofuel or biofuel precursor using engineered microbes. Some aspects of this invention relate to the discovery of a key regulator of lipid metabolism in microbes. Some aspects of this invention relate to engineered microbes for biofuel or biofuel precursor production.
Abstract: The present invention relates to the field of veterinary parasitology, especially of canine Babesiosis. In particular the invention relates to a polypeptide being a novel canine Babesia antigen (CBA), or fragments thereof, and to compositions comprising this antigen, to nucleic acids encoding the antigen, antibodies against the antigen, and medical uses of this antigen, fragments, antibodies, or encoding nucleic acids. In particular the invention relates to the use of such components in vaccines against canine Babesiosis.
Type:
Application
Filed:
December 2, 2014
Publication date:
March 19, 2015
Inventors:
Theodorus Petrus Maria Schetters, Karina Moubri-Menage, Jos Kleuskens, Andreas Walter Claudius Rohwer
Abstract: The present invention relates to a methodology for the generation of infectious ribonucleoparticles (RNPs) of negative-strand RNA viruses, and in particular of non-segmented negative-strand RNA viruses in yeast, especially in budding yeast. Accordingly, the patent application relates to a recombinant yeast strain suitable for the rescue of infectious non-segmented negative-strand RNA virus particles or infectious virus-like particles. The invention also relates to the use of the recombinant yeast to prepare vaccine seed and to the use of the produced RNPs or RNPs-like to prepare vaccine formulations. It also concerns the use of the recombinant yeast for the screening of libraries of DNA.
Type:
Grant
Filed:
January 30, 2009
Date of Patent:
March 17, 2015
Assignees:
Institut Pasteur, Centre National de la Recherche Scientifique
Inventors:
Chaouki Miled, Frédéric Tangy, Yves Jacob
Abstract: The present invention relates to methods, systems and compositions, including genetically modified microorganisms, directed to achieve decreased microbial conversion of 3-hydroxypropionic acid (3-HP) to aldehydes of 3-HP. In various embodiments this is achieved by disruption of particular aldehyde dehydrogenase genes, including multiple gene deletions. Among the specific nucleic acids that are deleted whereby the desired decreased conversion is achieved are aldA, aldB, puuC), and usg of E. coli. Genetically modified microorganisms so modified are adapted to produce 3-HP, such as by approaches described herein.
Type:
Application
Filed:
May 12, 2014
Publication date:
March 12, 2015
Applicant:
OPX Biotechnologies, Inc.
Inventors:
Michael D. Lynch, Christopher P. Mercogliano, Matthew L. Lipscomb, Tanya E. W. Lipscomb
Abstract: The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes.
Type:
Application
Filed:
August 7, 2014
Publication date:
March 12, 2015
Applicants:
Aventis Pharma S.A., Institut National de la Santé et de la Recherche Médicale
Abstract: The present invention relates to polypeptides and their uses as apelin inhibitors. More particularly, the present invention relates to a polypeptide comprising the sequence as set forth in SEQ ID NO:1 wherein at least one arginine residue at position 18, 19, 22 or 23 has been substituted or deleted.
Abstract: The present disclosure provides engineered transaminase polypeptides for the production of amines, polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to prepare compounds useful in the production of active pharmaceutical agents. The present disclosure provides engineered polypeptides having transaminase activity, polynucleotides encoding the polypeptides, methods of the making the polypeptides, and methods of using the polypeptides for the biocatalytic conversion of ketone substrates to amine products. The present enzymes have been engineered to have one or more residue differences as compared to the amino acid sequence of the naturally occurring transaminase of Vibrio fluvialis. In particular, the transaminases of the present disclosure have been engineered for efficient formation of chiral tryptamine derivatives from its corresponding prochiral ketone substrates.
Type:
Application
Filed:
March 22, 2013
Publication date:
March 12, 2015
Inventors:
Jovana Nazor, Derek Smith, Michael Crowe, Shiwei Song, Steven J. Collier
Abstract: The present disclosure provides, in various aspects, engineered alcohol tolerant yeast and methods of producing high concentrations of ethanol.
Type:
Application
Filed:
September 5, 2014
Publication date:
March 12, 2015
Applicants:
Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research
Inventors:
Felix Lam, Gerald Fink, Gregory Stephanopoulos
Abstract: Some aspects of this disclosure provide compositions, methods, and kits for improving the specificity of RNA-programmable endonucleases, such as Cas9. Also provided are variants of Cas9, e.g., Cas9 dimers and fusion proteins, engineered to have improved specificity for cleaving nucleic acid targets. Also provided are compositions, methods, and kits for site-specific recombination, using Cas9 fusion proteins (e.g., nuclease-inactivated Cas9 fused to a recombinase catalytic domain). Such Cas9 variants are useful in clinical and research settings involving site-specific modification of DNA, for example, genomic modifications.
Type:
Application
Filed:
June 30, 2014
Publication date:
March 12, 2015
Applicant:
President and Fellows of Harvard College
Inventors:
David R. Liu, John Paul Guilinger, David B. Thompson
Abstract: The embodiments described herein pertain to cells, and methods for preparing cells, that can be used as biocatalysts by altering enzymes that compete for a substrate or product of a pathway of interest such that the targeted enzyme is sensitive to a site-specific protease, which protease is expressed but relocated in the cell to a site where it is not in contact with the targeted enzyme in the intact cell. Upon cell lysis, the protease contacts the target enzyme, which is then inactivated by protease cleavage.
Type:
Application
Filed:
November 14, 2014
Publication date:
March 5, 2015
Applicants:
The Board of Trustees of the Leland Stanford Junior University, GreenLight Biosciences, Inc.
Abstract: The invention relates to compositions and methods, including polynucleotide sequences, amino acid sequences, recombinant host cells and recombinant host cell cultures engineered to produce fatty acid derivative compositions comprising fatty acids, fatty alcohols, fatty aldehydes, fatty esters, alkanes, terminal olefins, internal olefins or ketones. The fatty acid derivative composition is produced extracellularly with a higher titer, yield or productivity than the corresponding wild type or non-engineered host cell.
Type:
Application
Filed:
April 2, 2013
Publication date:
March 5, 2015
Applicant:
REG LIFE SCIENCES, LLC
Inventors:
Derek L. Greenfield, Andreas W. Schirmer, Elizabeth J. Clarke, Eli S. Groban, Bernardo M. Da Costa, Zhihao Hu
Abstract: The invention relates to methods for producing mogrosides with the aid of enzymes. In particular the invention proposes various biosynthetic pathways useful for mogroside production and enzymes useful for mogroside production are provided. Furthermore, the invention provides recombinant hosts useful in performing the methods of the invention.
Abstract: The present invention relates to methods for controlling pest infestation using double stranded RNA molecules. The invention provides methods for producing transgenic cells expressing the double stranded RNA molecules, as well as compositions and commodity products containing or treated with such molecules.
Type:
Application
Filed:
September 12, 2014
Publication date:
March 5, 2015
Applicant:
DEVGEN NV
Inventors:
Romaan RAEMAEKERS, Pascale FELDMANN, Geert PLAETINCK, Irene NOOREN, Els VAN BLEU, Frederic PECQUEUR, Laurent KUBLER, Nicole DAMME, Lies DEGRAVE, Isabel REMORY, Thierry BOGAERT
Abstract: A polypeptide conferring an acid-tolerant property on a yeast cell, a polynucleotide encoding the polypeptide, a yeast cell including an increased amount of the polypeptide, a method of producing a product by using the yeast cell, and a method of producing an acid-tolerant yeast cell are provided.
Type:
Application
Filed:
September 2, 2014
Publication date:
March 5, 2015
Inventors:
WOO YONG LEE, CHANG DUK KANG, JU YOUNG LEE, KWANG MYUNG CHO
Abstract: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided.
Type:
Application
Filed:
November 14, 2014
Publication date:
March 5, 2015
Inventors:
DANIEL M. GORMAN, TROY D. RANDALL, ALBERT ZLOTNIK
Abstract: The present disclosure provides a non-naturally occurring microorganism comprising: one or more polynucleotides encoding one or more enzymes in a pathway that produces acetyl-CoA; one or more polynucleotides encoding one or more enzymes in a pathway that catalyze a conversion of crotonyl alcohol, 5-hydroxy-3-ketovaleryl-CoA, 3-ketopent-4-enoyl-CoA, or 3,5-ketovaleryl-CoA to butadiene; one or more polynucleotides encoding one or more enzymes in a pathway that catalyze a conversion of dihydroxyacetone-phosphate to 1-propanol and/or 1,2-propanediol, wherein the microorganism has reduced levels of pyruvate decarboxylase enzymatic activity (e.g., the microorganism comprises a disruption of one or more enzymes that decarboxylate pyruvate and/or a disruption of one or more transcription factors of one or more enzymes that decarboxylate pyruvate), and wherein the microorganism is capable of growing on a C6 sugar as a sole carbon source under anaerobic conditions.
Type:
Application
Filed:
September 5, 2014
Publication date:
March 5, 2015
Inventors:
Johana Rincones Perez, Juan Diego Rojas Rojas, Ane Fernanda Beraldi Zeidler, Aline Silva Romao Dumaresq, Marilene Elizabete Pavan Rodrigues, Iuri Estrada Gouvea, Felipe Galzerani, Daniel Johannes Koch, Lucas Pedersen Parizzi, Mateus Schreiner Garcez Lopes, Thomas Martin Halder, Antonio Luis Ribeiro De Castro Morschbacker, Avram Michael Slovic
Abstract: The present disclosure provides a non-naturally occurring microorganism comprising: one or more polynucleotides encoding one or more enzymes in a pathway that produces acetyl-CoA; one or more polynucleotides encoding one or more enzymes in a pathway that catalyze a conversion of cytosolic acetyl-CoA to 2-propanol; one or more polynucleotides encoding one or more enzymes in a pathway that catalyze a conversion of dihydroxyacetone-phosphate to 1-propanol and/or 1,2-propanediol, wherein the microorganism has reduced levels of pyruvate decarboxylase enzymatic activity (e.g., the microorganism comprises a disruption of one or more enzymes that decarboxylate pyruvate and/or a disruption of one or more transcription factors of one or more enzymes that decarboxylate pyruvate), and wherein the microorganism is capable of growing on a C6 sugar as a sole carbon source under anaerobic conditions.
Type:
Application
Filed:
September 5, 2014
Publication date:
March 5, 2015
Inventors:
Johana Rincones Perez, Juan Diego Rojas Rojas, Ane Fernanda Beraldi Zeidler, Aline Silva Romao Dumaresq, Marilene Elizabete Pavan Rodrigues, Iuri Estrada Gouvea, Felipe Galzerani, Daniel Johannes Koch, Lucas Pedersen Parizzi, Mateus Schreiner Garcez Lopes, Thomas Martin Halder, Antonio Luis Ribeiro De Castro Morschbacker, Avram Michael Slovic
Abstract: Drug compositions, fusions and conjugates are provided. The drug fusions and conjugates contain a therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The drug compositions, fusions and conjugates have a longer in vivo half-life in comparison with the unconjugated or unfused therapeutic or diagnostic agent.
Abstract: A high flux in conversion of pyruvate to acetolactate was achieved in yeast through expression of acetolactate synthase in the cytosol in conjunction with reduction in pyruvate decarboxylase activity. Additional manipulations to improve flux to acetolactate are reduced pyruvate dehydrogenase activity and reduced glycerol-3-phosphate dehydrogenase activity. Production of compounds having acetolactate as an upstream intermediate benefit from the increased conversion of pruvate to acetolactate in the described strains.
Type:
Grant
Filed:
January 22, 2014
Date of Patent:
March 3, 2015
Assignee:
Butamax Advanced Biofuels LLC
Inventors:
Larry Cameron Anthony, Lori Ann Maggio-Hall
Abstract: The present invention relates to an antibody, recombinant or synthetic antigen-binding fragments thereof able to recognise and bind an epitope comprised in the spacer domain of ADAMTS-5, nucleic acid and expression vector encoding the same, method of production and uses thereof.
Type:
Application
Filed:
April 12, 2013
Publication date:
February 26, 2015
Inventors:
Riccardo Chiusaroli, Michela Visintin, Gianfranco Caselli, Lucio Claudio Rovati
Abstract: The present disclosure relates generally to multi-specific Fab fusion proteins (MSFP) which comprise an antibody Fab fragment with both N-termini fused to a fusion moiety (fusion moiety A or B). MSFP containing the Fab fragment exhibit significantly reduced binding ability of the Fab fragment to the Fab target. Binding of the Fab to its target is restored when the MSFP is clustered on a cell surface by binding of the fusion moieties to their target. The reduced binding of the Fab to its target, especially when presented on a cell surface in its native state, absent fusion moiety binding provides advantages such as: reduced side effects and allows desirable pharmacological effects of selectivity and specificity in a controlled manner.
Abstract: The invention relates to cells, nucleic acids, and enzymes, the use thereof for producing sophorolipids, and methods for producing sophorolipids.
Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant.
Type:
Application
Filed:
August 22, 2014
Publication date:
February 26, 2015
Inventors:
Olaf SCHNEEWIND, Alice G. Cheng, Dominique M. Missiakas, Hwan Keun Kim
Abstract: The invention relates to cells, nucleic acids, and enzymes, the use thereof for producing sophorolipids, and methods for producing sophorolipids.
Abstract: Compositions are provided, which can be used as frameworks for the creation of very stable and soluble single-chain Fv antibody fragments. These frameworks have been selected for intracellular performance and are thus ideally suited for the creation of scFv antibody fragments or scFv antibody libraries for applications where stability and solubility are limiting factors for the performance of antibody fragments, such as in the reducing environment of a cell. Such frameworks can also be used to identify highly conserved residues and consensus sequences which demonstrate enhanced solubility and stability.
Type:
Application
Filed:
August 26, 2014
Publication date:
February 26, 2015
Inventors:
Kathrin Tissot, Stefan Ewert, Adrian Auf Der Maur, Alcide Barberis, Dominik Escher
Abstract: The invention relates to cells, nucleic acids, and enzymes, the use thereof for producing sophorolipids, and methods for producing sophorolipids.
Abstract: The invention relates to cells, nucleic acids, and enzymes, the use thereof for producing sophorolipids, and methods for producing sophorolipids.
Abstract: The present invention provides various combinations of genetic modifications to a transformed host cell that provide increase conversion of carbon to a chemical product. The present invention also provides methods of fermentation and methods of making various chemical products.
Type:
Application
Filed:
March 17, 2014
Publication date:
February 26, 2015
Inventors:
Hans LIAO, Christopher Patrick MERCOGLIANO, Travis Robert WOLTER, Michael Tai Man LOUIE, Wendy Kathleen RIBBLE, Tanya LIPSCOMB, Eileen Colie SPINDLER, Michael D LYNCH
Abstract: A hydrocarbon synthase gene encoding protein having excellent capacity to synthesize a hydrocarbon such as alkane and novel functions is provided. The gene encodes a protein comprising an amino acid sequence comprising a motif sequence shown in SEQ ID NO: 1 and having activity of synthesizing a hydrocarbon with a carbon number one less than that of an aldehyde compound from the aldehyde compound.
Abstract: The present invention relates to a hydantoinase having an amino acid sequence selected from (i) or (ii), with (i) amino acid sequence selected from SEQ ID NO: 6-20 and SEQ ID NO: 73-119 (ii) amino acid sequence wherein in the amino acid sequence of SEQ ID NO: 6-20 and SEQ ID NO: 73-119, 1 to 75 amino acid residues have been substituted, deleted, inserted and/or added, and wherein further the catalytic activity of the hydantoinase is higher by a factor of at least 1.2 than the catalytic activity of the hydantoinase having amino acid sequence SEQ ID NO: 1, The present invention further relates to a process for preparing amino acids, wherein said hydantoinase is used.
Type:
Application
Filed:
November 16, 2012
Publication date:
February 26, 2015
Inventors:
Steffen Osswald, Heiko Schuster, Jürgen Roos, Andreas Karau, Ulrich Schwaneberg, Ronny Martinez, Hemanshu Mundhada, Ursula Holter
Abstract: The present invention relates to an anti-idiotypic polypeptide scaffold that includes two or more peptide sequences that mimic a discontinuous epitope of a pathogen that is recognized by or induces formation of a broadly neutralizing antibody. Using a fibronectin FNfn10 scaffold bearing two or more modified discontinuous loops, scaffolds that recognize broadly neutralizing antibodies in vitro and from patient serum have been identified. These scaffolds should induce an immune response or mobilize germline specificities to initiate their affinity maturation.
Abstract: A method for producing a strain of Saccharomyces cerevisiae with introduced genes coding for xylose reductase, xylitol dehydrogenase and xylulokinase and with improved ethanol production, improved xylose conversion, reduced xylitol production and improved inhibitor tolerance is described. The method comprises culturing a strain of Saccharomyces cerevisiae at a continuous mode with a medium comprising essentially only xylose as carbon source at a temperature of 25-38° C., preferably 30-35° C., and an airflow of 0.040-0.055 vvm, and increasing the dilution rate to maintain a constant cell level, said cell level being in the range of 1.5-3.0 determined by optical density or equivalent analytical means, and adding at least one inhibitor to the cells and gradually increasing the addition of said inhibitor. Further, strains of Saccharomyces cerevisiae obtained by the method according to the invention are described.
Type:
Grant
Filed:
November 15, 2011
Date of Patent:
February 24, 2015
Assignee:
Scandinavian Technology Group AB
Inventors:
Eva Albers, Lisbeth Olsson, Rakesh Koppram
Abstract: Disclosed are yeast-based immunotherapeutic compositions, hepatitis B virus (HBV) antigens, and fusion proteins for the treatment and/or prevention of HBV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HBV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HBV and/or symptoms thereof.
Type:
Grant
Filed:
February 19, 2014
Date of Patent:
February 24, 2015
Assignee:
GlobeImmune, Inc.
Inventors:
David Apelian, Thomas H. King, Zhimin Guo, Claire Coeshott
Abstract: A ligand recombinant protein inhibiting HB-EGF (Heparin-Binding Epidermal Growth Factor like), from the R domain of diphtheria toxin, which can be used for the treatment and diagnosis of diseases involving the activation of the HB-EGF/EGFR pathway.
Type:
Application
Filed:
March 19, 2013
Publication date:
February 19, 2015
Applicant:
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENE ALT
Inventors:
Daniel Gillet, Benoit Villiers, Sylvain Pichard, Bernard Maillere, Alain Sanson
Abstract: Provided herein are non-naturally occurring microbial organisms having a formaldehyde fixation pathway and a formate assimilation pathway, which can further include a methanol metabolic pathway, a methanol oxidation pathway, a hydrogenase and/or a carbon monoxide dehydrogenase. These microbial organisms can further include a butadiene, 1,3-butanediol, crotyl alcohol or 3-buten-2-ol pathway. Additionally provided are methods of using such microbial organisms to produce butadiene, 1,3-butanediol, crotyl alcohol or 3-buten-2-ol.
Type:
Application
Filed:
March 14, 2014
Publication date:
February 19, 2015
Applicant:
Genomatica, Inc.
Inventors:
Anthony P. BURGARD, Robin E. OSTERHOUT, Priti PHARKYA, Stefan ANDRAE